Curemark to begin tests of drug in autism victims
Curemark LLC, a Rye-based drug research and development company focused on neurological diseases, said that it has received regulatory clearance to start a drug testing program.
The tests, designed to study the effectiveness of Curemark’s CM-AT medication as an autism treatment, are expected to begin the tests at multiple sites across the country during the second quarter.
“With 1 in 150 children diagnosed with autism, we have children who are suffering,” Dr. Joan Fallon, Curemark’s chief executive officer, said in a written statement. “We are very excited about the opportunity to enter a Phase III trial for this ever-growing population of children.”